Inn‐Wen Chong

4.1k total citations
140 papers, 2.9k citations indexed

About

Inn‐Wen Chong is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Inn‐Wen Chong has authored 140 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 35 papers in Molecular Biology and 31 papers in Infectious Diseases. Recurrent topics in Inn‐Wen Chong's work include Lung Cancer Treatments and Mutations (23 papers), Tuberculosis Research and Epidemiology (21 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Inn‐Wen Chong is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Tuberculosis Research and Epidemiology (21 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Inn‐Wen Chong collaborates with scholars based in Taiwan, United States and Japan. Inn‐Wen Chong's co-authors include Jong‐Rung Tsai, Jhi‐Jhu Hwang, Ming‐Shyan Huang, Chih‐Jen Yang, Chau‐Chyun Sheu, Jen‐Yu Hung, Shah‐Hwa Chou, Shiu‐Ru Lin, Po‐Len Liu and Wei‐An Chang and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Inn‐Wen Chong

135 papers receiving 2.8k citations

Peers

Inn‐Wen Chong
Nannan Zhang China
Liangqing Zhang China
Gianluigi Zaza Italy
Sukhwinder Singh Sohal Australia
Chih‐Jen Yang Taiwan
Faguang Jin China
Sascha David Germany
Michael J. Weyant United States
Eman A. Toraih Egypt
Limin Peng United States
Nannan Zhang China
Inn‐Wen Chong
Citations per year, relative to Inn‐Wen Chong Inn‐Wen Chong (= 1×) peers Nannan Zhang

Countries citing papers authored by Inn‐Wen Chong

Since Specialization
Citations

This map shows the geographic impact of Inn‐Wen Chong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inn‐Wen Chong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inn‐Wen Chong more than expected).

Fields of papers citing papers by Inn‐Wen Chong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inn‐Wen Chong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inn‐Wen Chong. The network helps show where Inn‐Wen Chong may publish in the future.

Co-authorship network of co-authors of Inn‐Wen Chong

This figure shows the co-authorship network connecting the top 25 collaborators of Inn‐Wen Chong. A scholar is included among the top collaborators of Inn‐Wen Chong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inn‐Wen Chong. Inn‐Wen Chong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tsai, Jih‐Jin, Shyh‐Shin Chiou, Po‐Chih Chen, et al.. (2024). The epidemiology and phylogenetic trends of Omicron subvariants from BA.5 to XBB.1 in Taiwan. Journal of Infection and Public Health. 17(11). 102556–102556. 2 indexed citations
2.
3.
Huang, Hung‐Ling, Meng‐Rui Lee, Wei‐Chang Huang, et al.. (2024). Sputum bacterial microbiota signature as a surrogate for predicting disease progression of nontuberculous mycobacterial lung disease. International Journal of Infectious Diseases. 149. 107085–107085. 3 indexed citations
4.
Tsai, Ming‐Ju, Jen‐Yu Hung, Mei‐Hsuan Lee, et al.. (2024). Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung. The Kaohsiung Journal of Medical Sciences. 40(5). 467–476. 1 indexed citations
5.
Wu, Deng‐Chyang, Chia‐Chen Ku, Jia-Bin Pan, et al.. (2023). Heterogeneity of Phase II Enzyme Ligands on Controlling the Progression of Human Gastric Cancer Organoids as Stem Cell Therapy Model. International Journal of Molecular Sciences. 24(21). 15911–15911. 5 indexed citations
6.
Liu, Li‐Teh, Jih‐Jin Tsai, Justin Jang Hann Chu, et al.. (2023). The identification and phylogenetic analysis of SARS‐CoV‐2 delta variants in Taiwan. The Kaohsiung Journal of Medical Sciences. 39(6). 624–636. 8 indexed citations
7.
Lee, Meng‐Rui, Hung‐Ling Huang, Li‐Ta Keng, et al.. (2021). Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort Study. Journal of Fungi. 7(6). 480–480. 11 indexed citations
8.
Wu, Kuan‐Li, Hsiao‐Ling Chen, Ying‐Ming Tsai, et al.. (2021). First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine. 10(19). 4376–4376. 10 indexed citations
9.
Tsai, Yu-Chen, Hsiao‐Ling Chen, Kuan‐Li Wu, et al.. (2021). Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis. Cancers. 14(1). 182–182. 18 indexed citations
10.
Chuang, Cheng‐Hao, Hsiao‐Ling Chen, Yu-Chen Tsai, et al.. (2021). Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer. Cancers. 13(8). 1966–1966. 37 indexed citations
11.
Chen, Hsiao‐Ling, Yu‐Kang Tu, Kuan‐Li Wu, et al.. (2020). Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma. Cancers. 12(12). 3629–3629. 23 indexed citations
12.
Huang, Hung‐Ling, Meng‐Hsuan Cheng, Po‐Liang Lu, et al.. (2019). Outcome of patients with and poor prognostic factors for Mycobacterium kansasii-pulmonary disease. Respiratory Medicine. 151. 19–26. 11 indexed citations
13.
Lee, Meng‐Rui, Hung‐Ling Huang, Shu‐Wen Lin, et al.. (2019). Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI. Journal of Clinical Medicine. 8(6). 812–812. 21 indexed citations
14.
Cheng, Meng‐Hsuan, Hung‐Ling Huang, Yen‐You Lin, et al.. (2019). BA6 Induces Apoptosis via Stimulation of Reactive Oxygen Species and Inhibition of Oxidative Phosphorylation in Human Lung Cancer Cells. Oxidative Medicine and Cellular Longevity. 2019. 1–21. 39 indexed citations
15.
Huang, Hung‐Ling, Meng‐Rui Lee, Meng‐Hsuan Cheng, et al.. (2019). Predictors of radiographic progression for NTM–pulmonary disease diagnosed by bronchoscopy. Respiratory Medicine. 161. 105847–105847. 4 indexed citations
16.
17.
Huang, Hung‐Ling, Meng‐Hsuan Cheng, Po‐Liang Lu, et al.. (2017). Epidemiology and Predictors of NTM Pulmonary Infection in Taiwan - a Retrospective, Five-Year Multicenter Study. Scientific Reports. 7(1). 16300–16300. 64 indexed citations
18.
Wang, Jaw‐Yuan, Shu‐Wen Jao, Chien-Yu Lu, et al.. (2006). Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: Correlation to activated K-ras oncogene. Oncology Reports. 16(6). 1245–52. 30 indexed citations
19.
Cheng, Tian‐Lu, Mei‐Yin Chang, Chau‐Chyun Sheu, et al.. (2005). Overexpression of Circulating c-Met Messenger RNA Is Significantly Correlated With Nodal Stage and Early Recurrence in Non-Small Cell Lung Cancer. CHEST Journal. 128(3). 1453–1460. 41 indexed citations
20.
Hung, Jen‐Yu, et al.. (2001). Pulmonary Metastasis of Hepatocellular Carcinoma. 16(2). 95–101. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nannan Zhang Breakdown of academic impact, for papers by Liangqing Zhang Breakdown of academic impact, for papers by Gianluigi Zaza Breakdown of academic impact, for papers by Sukhwinder Singh Sohal Breakdown of academic impact, for papers by Chih‐Jen Yang Breakdown of academic impact, for papers by Faguang Jin Breakdown of academic impact, for papers by Sascha David Breakdown of academic impact, for papers by Michael J. Weyant Breakdown of academic impact, for papers by Eman A. Toraih Breakdown of academic impact, for papers by Limin Peng
Rankless by CCL
2026